Latest Breaking News On - Matt granato - Page 1 : comparemela.com

FDA approves Merck's Winrevair | Drug Store News

FDA Approves Sotatercept, First-in-Class Treatment for Adults With PAH

Adults with pulmonary arterial hypertension (PAH) have a new treatment available with the FDA approval of sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic.

FDA Approves Merck's WINREVAIR, a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension

WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone

Merck's Winrevair earns FDA approval in milestone moment for PAH treatment

The FDA approval marks a milestone for Merck, which acquired the pulmonary arterial hypertension treatment in 2021 through its $11.5 billion buyout of Acceleron Pharma.

Pulmonary Arterial Hypertension Patients Receive Lifeline With FDA's Approval of New Drug